Clinical trials
Phase 3 Crohn Disease trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
120 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2002 | 3 |
| 2003 | 1 |
| 2004 | 6 |
| 2005 | 4 |
| 2006 | 8 |
| 2007 | 6 |
| 2008 | 3 |
| 2009 | 3 |
| 2010 | 4 |
| 2011 | 8 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 4 |
| 2015 | 4 |
| 2016 | 6 |
| 2017 | 9 |
| 2018 | 11 |
| 2019 | 4 |
| 2020 | 4 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 4 |
| 2024 | 9 |
| 2025 | 5 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 64 |
| Terminated | 24 |
| Recruiting | 18 |
| Active, not recruiting | 9 |
| Withdrawn | 3 |
| Unknown status | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AbbVie | 11 |
| Janssen Research & Development, LLC | 11 |
| Takeda | 10 |
| Abbott | 9 |
| Celgene | 7 |
| Eli Lilly and Company | 5 |
| UCB Pharma | 5 |
| GlaxoSmithKline | 4 |
| Shire | 4 |
| Mesoblast, Inc. | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Crohn Disease | 120 |
| Inflammatory Bowel Diseases | 22 |
| Colitis, Ulcerative | 15 |
| Colitis | 4 |
| Arthritis, Psoriatic | 2 |
| Anemia | 1 |
| Anemia, Iron-Deficiency | 1 |
| Arthritis, Juvenile | 1 |
| Colonic Neoplasms | 1 |
| Colonic Polyps | 1 |
Trials
Showing 1 to 25 of 120. Each trial links to its page on Pharma Observatory.
20 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.